CN114958694A - 一种联产共轭亚油酸和γ-氨基丁酸的鼠李糖乳杆菌及应用 - Google Patents
一种联产共轭亚油酸和γ-氨基丁酸的鼠李糖乳杆菌及应用 Download PDFInfo
- Publication number
- CN114958694A CN114958694A CN202210790287.7A CN202210790287A CN114958694A CN 114958694 A CN114958694 A CN 114958694A CN 202210790287 A CN202210790287 A CN 202210790287A CN 114958694 A CN114958694 A CN 114958694A
- Authority
- CN
- China
- Prior art keywords
- acid
- linoleic acid
- lactobacillus rhamnosus
- gamma
- conjugated linoleic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 title claims abstract description 112
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 title claims abstract description 72
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 title claims abstract description 58
- 229940108924 conjugated linoleic acid Drugs 0.000 title claims abstract description 57
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 title claims abstract description 56
- 229960003692 gamma aminobutyric acid Drugs 0.000 title claims abstract description 56
- 241000218588 Lactobacillus rhamnosus Species 0.000 title claims abstract description 50
- 238000000855 fermentation Methods 0.000 claims abstract description 51
- 230000004151 fermentation Effects 0.000 claims abstract description 51
- 239000001963 growth medium Substances 0.000 claims abstract description 20
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims abstract description 15
- 235000020778 linoleic acid Nutrition 0.000 claims abstract description 15
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000013922 glutamic acid Nutrition 0.000 claims abstract description 13
- 239000004220 glutamic acid Substances 0.000 claims abstract description 13
- 235000013361 beverage Nutrition 0.000 claims abstract description 7
- 238000004321 preservation Methods 0.000 claims abstract description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 18
- 239000008103 glucose Substances 0.000 claims description 18
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 9
- 238000009630 liquid culture Methods 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 238000011218 seed culture Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 claims description 8
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 claims description 8
- ISPYRSDWRDQNSW-UHFFFAOYSA-L manganese(II) sulfate monohydrate Chemical compound O.[Mn+2].[O-]S([O-])(=O)=O ISPYRSDWRDQNSW-UHFFFAOYSA-L 0.000 claims description 8
- 241000283690 Bos taurus Species 0.000 claims description 7
- 239000001888 Peptone Substances 0.000 claims description 7
- 108010080698 Peptones Proteins 0.000 claims description 7
- 235000019319 peptone Nutrition 0.000 claims description 7
- 210000000988 bone and bone Anatomy 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 4
- 235000019225 fermented tea Nutrition 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 238000012216 screening Methods 0.000 abstract description 17
- 235000013305 food Nutrition 0.000 abstract description 15
- 231100000350 mutagenesis Toxicity 0.000 abstract description 11
- 238000002703 mutagenesis Methods 0.000 abstract description 11
- 239000007788 liquid Substances 0.000 abstract description 9
- 241000186660 Lactobacillus Species 0.000 abstract description 4
- 229940039696 lactobacillus Drugs 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- 241000894006 Bacteria Species 0.000 description 16
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 241001122767 Theaceae Species 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 235000013616 tea Nutrition 0.000 description 7
- 239000007787 solid Substances 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 241000030538 Thecla Species 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 231100000225 lethality Toxicity 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- 235000010254 Jasminum officinale Nutrition 0.000 description 2
- 240000005385 Jasminum sambac Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000010170 biological method Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108010009004 proteose-peptone Proteins 0.000 description 2
- 210000004767 rumen Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- ADHNUPOJJCKWRT-JLXBFWJWSA-N (2e,4e)-octadeca-2,4-dienoic acid Chemical class CCCCCCCCCCCCC\C=C\C=C\C(O)=O ADHNUPOJJCKWRT-JLXBFWJWSA-N 0.000 description 1
- 206010000050 Abdominal adhesions Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000604448 Megasphaera elsdenii Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000021403 cultural food Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical group O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/166—Addition of, or treatment with, enzymes or microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/005—Amino acids other than alpha- or beta amino acids, e.g. gamma amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
- C12P7/6431—Linoleic acids [18:2[n-6]]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开一种联产共轭亚油酸和γ‑氨基丁酸的鼠李糖乳杆菌及其应用,该菌株于2022年5月13日保藏于中国典型培养物保藏中心,保藏编号为CCTCCM 2022615;本发明通过采用常压室温等离子体诱变技术,经过筛选得到能够高效联产共轭亚油酸和γ‑氨基丁酸的鼠李糖乳杆菌SG906,将此鼠李糖乳杆菌SG906接种至含有游离亚油酸和谷氨酸的培养基中发酵72h,发酵液中共轭亚油酸含量高达7.95g/L,γ‑氨基丁酸的含量高达178.32g/L,大大降低生产成本;本发明的鼠李糖乳杆菌SG906属于食品乳杆菌属,具有很好的安全性,可广泛应用于药物、保健品、饮料等领域,具有巨大的应用价值和市场开发潜力。
Description
技术领域
本发明具体涉及一种联产共轭亚油酸苯和γ-氨基丁酸的鼠李糖乳杆菌及应用,属于微生物技术领域。
背景技术
随着经济发展和人民生活水平的提高,肥胖引发的高血脂、Ⅱ型糖尿病、高血压和动脉粥样硬化、甚至恶性肿瘤等一系列疾病,对人体健康危害极大。因此,低价安全高效的营养保健用品是当前的研究热点。
共轭亚油酸(Conjugated linoleic acid,简称CLA)是含有共轭双键的十八碳二烯酸的多种位置异构体和几何异构体的总称,CLA的双键在碳链上主要有四种位置的排列方式:8,10-、9,11-、10,12-和11,13-,且由于共轭双键两端的碳原子都具有顺式(cis)和反式(trans)两种几何构型,即每种位置异构又具有cis-cis、cis-trans、trans-cis、trans-trans四种几何异构体,所以CLA异构体的种类众多,其中,c9,t11-CLA和t10,c12-CLA是含量最多且已经被证实具有生理活性的两种主要异构体。大量研究表明,它具有多种营养和保健功能,如抗癌、抗糖尿病、抗动脉粥样硬化、降低体脂含量、胰岛素抵抗、调节机体免疫等多种营养和保健功能。
天然的CLA主要存在于牛、羊等反刍动物的肉和乳制品中,含量极低,目前工业上普遍采用化学法合成CLA,但是存有试剂残留,成本高等问题。利用微生物合成CLA不需要高温高压,分离纯化步骤相对简单。已发现一些瘤胃菌、丙酸菌和乳酸菌等能合成CLA,但是瘤胃菌、痤疮丙酸杆菌、溶纤维丁酸弧菌、埃氏巨球形菌等细菌没有列入食用菌名录,不能直接食用。用食品安全级乳酸菌生产CLA可以直接应用于食品,因此,应用乳酸菌生产CLA将有广阔的应用前景,但是目前已报道的一些益生菌,如罗伊氏乳酸杆菌、乳酸乳球菌和短双歧杆菌生产CLA的效率很低。虽然CLA早在2009年就被中国卫计委批准列入新食品名录。但是,化学合成或生物合成的CLA价格昂贵,限制其在常规食品添加剂上的规模化应用。
γ-氨基丁酸(γ-amino butyric acid,简称GABA),是一种天然的功能性非蛋白质氨基酸,具有治疗糖尿病、降血压、防止肥胖、降血氨、改善睡眠、活化肝功能,改善更年期综合症等重要生理功能,在功能食品中的应用已成为研究热点,广泛应用于食品、药品和化妆品中。日本厚生省、欧洲食品***(EFSA)和美国食品药品管理局(FDA)承认乳酸菌发酵生产的GABA为天然食品添加剂,我国***2009年批准此类GABA为新资源食品。目前,合成GABA的方法分有化学法和生物法;化学法存在吡咯烷酮残留、副反应多等问题,不能应用于食品领域;生物法包括植物富集法和微生物法,发芽的糙米和豆类均含有大量的γ-氨基丁酸,但是提取成本高无法大规模生产。微生物由于生长周期短,繁殖速度快,近些年广泛被应用于生产GABA,已发现一些大肠杆菌、短乳杆菌、副断乳杆菌、酵母、霉菌等能合成GABA,但是由于发酵液成分复杂,提取高品质GABA成本高,价格昂贵,不利于工业化生产。
乳酸菌作为一种食品安全级(GRAS)的微生物具有各种保健功效,常作为益生菌添加于食品中以增进人体健康,其中鼠李糖乳杆菌是人体肠道菌群之一,乳杆菌属鼠李糖乳杆菌(Lactobacillus rhamnosus),是人体正常菌群之一,肠道黏着率高,定植能力强,并具有高效降胆固醇,促进细胞***,可起到调节肠道菌群、预防和治疗腹泻、排除毒素、预防龋齿、提高机体免疫力及抗癌等重要的生理保健功能,也是功能研究较多的乳杆菌,广泛应用于酸奶、奶酪和固体饮料等食品的生产中。
现有技术中,一般的功能食品都是通过外添加的方式使其富含CLA或者GABA,而天然或微生物合成的高纯CLA和GABA价格较贵,限制了CLA和GABA的大规模应用。大量研究表明乳酸菌具有合成CLA或者GABA的能力,现有技术中尝试将产CLA或GABA的菌种应用到食品中,但是大部分学者筛选到的产CLA或GABA的菌株有的产量过低,有的只能生产CLA或GABA,有的菌株非安全菌株,不允许在食品中应用或者在食品培养配方中不能生长。
发明内容
为了解决上述技术问题,本发明提供一种联产共轭亚油酸和γ-氨基丁酸的鼠李糖乳杆菌及其应用,本发明的鼠李糖乳杆菌在高产CLA的同时GABA的产量也能达到较高的水平,有效促进功能活性成分多优并举,达到功能多效叠加的目的,在食品、保健品和药品领域具有重要的应用价值。
本发明的目的一在于一种联产共轭亚油酸和γ-氨基丁酸的鼠李糖乳杆菌,所述发酵联产共轭亚油酸和γ-氨基丁酸的鼠李糖乳杆菌SG906于2022年5月13日保藏于中国典型培养物保藏中心(CCTCC),保藏编号为CCTCC M 2022615,保藏地址为中国武汉,武汉大学,邮编:430072。
本发明提供的发酵联产共轭亚油酸和γ-氨基丁酸的鼠李糖乳杆菌的形态学及生理化学特征如下:
菌落颜色:乳白色
需氧方式:兼性厌氧
适宜生长温度:35℃-37℃
适宜生长pH:5-6
菌落形态:杆状
革兰氏染色:阳性。
本发明目的二在于提供一种鼠李糖乳杆菌在发酵联产共轭亚油酸和γ-氨基丁酸中的应用。
本发明的目的三在于提供一种联产共轭亚油酸和γ-氨基丁酸的方法,采用本发明提供的鼠李糖乳杆菌SG906依次经过活化培养、种子培养、发酵罐补料反馈培养高效联产共轭亚油酸和γ-氨基丁酸。
进一步的,所述发酵罐内液体培养基pH为6.0~6.5,包括如下按质量百分比计的组份:葡萄糖0.5%,牛大骨蛋白胨2%,酵母粉2%,七水硫酸镁0.03%,一水硫酸锰0.01%,吐温-80 0.2%,谷氨酸5%,亚油酸0.2%,其余为水。
进一步的,所述发酵罐培养周期划分为两个阶段:
(1)在发酵培养起始阶段,初始葡萄糖的浓度控制在30g/L,通过流加70%的葡萄糖控制发酵体系中的残糖(以葡萄糖计)为0.5-1.0g/L;
(2)在发酵罐内OD600达到25后,通过流加亚油酸和谷氨酸控制发酵体系中的亚油酸浓度保持在0.01-0.1g/L和谷氨酸的浓度保持在1-5g/L;
其中,所述发酵罐培养全过程控制溶解氧在20-45%。
本发明目的四在于提供一种鼠李糖乳杆菌在复合功能发酵茶饮料中的应用。
相较于现有技术,本发明的有益效果在于:
1、本发明采用常温常压等离子体诱变技术,首次发现能够高效联产共轭亚油酸和γ-氨基丁酸的鼠李糖乳杆菌SG906,该菌株经过分批补料发酵,发酵液中共轭亚油酸的浓度最高可达7.95g/L,以亚油酸为底物转化率达到80.72%,发酵液中γ-氨基丁酸的浓度最高可达178.30g/L,转化率达98.56%,证实了本发明提供的鼠李糖乳杆菌SG906极具工业化运用价值。
2、本发明提供的鼠李糖乳杆菌SG906是食品安全乳酸菌,在商业上广泛应用的一种益生菌种,同时兼具联产共轭亚油酸和γ-氨基丁酸的能力,可广泛地应用于制备富含CLA和GABA的复合功能保健品、食品、食品添加剂或饮料,大幅降低制备成本,具有广阔的应用前景。
附图说明
图1为本发明实施例1中鼠李糖乳杆菌CICC 22152诱变致死率曲线;
图2为本发明实施例1中鼠李糖乳杆菌CICC 22152和优良突变株96孔板初筛发酵结果示意图;
图3为本发明实施例2中鼠李糖乳杆菌CICC 22152和优良突变株摇瓶复筛发酵结果示意图;
图4为本发明实施例2中鼠李糖乳杆菌SG906 20L发酵罐发酵曲线图。
具体实施方式
下面结合附图和较佳实施例对本发明做进一步的说明,在本发明中所披露的范围的端点和任何值都不限于该精确的范围或值,这些范围或值应当理解为包含接近这些范围或值的值;对于数值范围来说,各个范围的端点值之间、各个范围的端点值和单独的点值之间,以及单独的点值之间可以彼此组合而得到一个或多个新的数值范围,这些数值范围应被视为在本文中具体公开;
以下实施例中所使用的实验方法如无特殊说明,实施例中未注明具体条件的实验方法,通常按照常规条件,下述实施例中所使用的材料、试剂等,如无特殊说明,均可从商业途径得到;
以下实施例中的定量试验,均设置三次重复实验,结果取平均值;
下述实施例中共轭亚油酸的检测:照中华人民共和国轻工行业标准QB/T5403-2019共轭亚油酸检测方法进行检测;
γ-氨基丁酸的检测:参照中华人民共和国轻工行业标准QB/T4587-2013γ-氨基丁酸检测方法进行检测。
实施例1鼠李糖乳杆菌及其诱变筛选
一种鼠李糖乳杆菌,经由源于中国工业微生物菌种保藏管理中心的出发菌鼠李糖乳杆菌CICC 22152经常压室温等离子体诱变筛选,进而得到所述鼠李糖乳杆菌SG906;
其中,鼠李糖乳杆菌SG906的诱变筛选方法,包括如下步骤:
S1、诱变预处理:将出发菌鼠李糖乳杆菌CICC 22152的甘油菌100μL接种至5mLMRS液体培养基培养,在37℃下静置培养至菌液OD600值为1.0,在8000rpm的转速下离心处理10min,弃上清液收集菌体,用含5%(v/v)甘油的生理盐水洗涤菌体两遍,并重悬制成分散均匀的菌悬液,调整细菌的终浓度为100~110CFU·mL-1;
S2、常压室温等离子体诱变:取20μL经过步骤S1制得的菌悬液均匀涂于无菌载片上表面,干燥后用镊子将载片转移至载物台,采用高纯氦气作为等离子体的工作气体,设置电源功率50W,照射距离4mm,等离子体的温度为26℃,气流量为10L/min,处理菌物载片,进行常压室温等离子体诱变处理,照射时间分别取0(对照)、5、10、15、20、25、30、35、40、45、50、55s;处理后将载片转移到1.5mL的EP管中,在振荡器上再生培养60min,再用含5%(v/v)甘油的生理盐水稀释10倍,形成新的菌悬液;
其中,将菌悬液涂布于MRS固体培养基平板后置于37℃培养箱内培养,培养48h,观察菌株生长情况,统计菌落数,绘制致死率曲线(如图1所示),选择致死率为75%的处理时间;
S3、诱变后培养:样品诱变处理完毕后,取经过步骤S2获得的新的菌悬液200μL涂布于MRS固体培养基,37℃静置培养48h分离单克隆;
S4、初筛:采用96孔板对诱变分离的突变株进行初筛,挑取单克隆到含1mL初筛液体培养基的96孔板培养,培养条件37℃,100rpm,培养72h,离心收集上清液,检测上清液中共轭亚油酸和γ-氨基丁酸含量,筛选共轭亚油酸和γ-氨基丁酸含量高的菌种,共筛选的到三株高产突变株作为初筛菌株,分别命名SG253、SG906、SG1158,并进行甘油保藏,三株菌株的共轭亚油酸和γ-氨基丁酸产量如图2所示;其中,初筛液体培养基包含如下质量百分数成分:葡萄糖0.3%,牛大骨蛋白胨1%,酵母粉1%,七水硫酸镁0.02%,一水硫酸锰0.005%,吐温-80 0.1%,谷氨酸6%,亚油酸0.02%,其余为水,pH调至6.0;
S5、复筛:将经过步骤S4初筛获取的优良突变株和对照菌的甘油菌分别按5%接种量,接种至MRS固体培养基上培养,再取1mL甘油菌液接种至25mL复筛种子培养基培养,摇管装液量50%(v/v),培养温度为37℃,静置培养时间48h;其中,复筛种子培养基包含如下质量百分数成分:葡萄糖0.2%,牛大骨蛋白胨0.5%,酵母粉0.5%,七水硫酸镁0.01%,一水硫酸锰0.002%,吐温-800.1%,其余为水,pH调至6.0;复筛种子培养基中的种液按15%接种量取18.75mL种子培养液接种至125mL复筛发酵培养基培养,250mL摇瓶装液量125mL,发酵温度37℃,静置发酵72h,然后离心收集上清液;其中,复筛发酵培养基包含如下质量百分数成分:葡萄糖0.3%,牛大骨蛋白胨2%,酵母粉1.5%,七水硫酸镁0.03%,一水硫酸锰0.01%,吐温-80 0.2%,谷氨酸6%,亚油酸0.1%,其余为水,pH调至6.0;参见图3,检测上清液共轭亚油酸和γ-氨基丁酸的含量,筛选出高产菌株鼠李糖乳杆菌SG906,该菌经72h摇瓶发酵,发酵液中共轭亚油酸达到0.76g/L,与对照菌相比提高7.6倍,γ-氨基丁酸浓度达到15.2g/L,与对照菌相比提高25.3倍;
上述诱变筛选方法中,MRS液体培养基包含如下质量百分数成分:酪蛋白胨1%,牛肉膏1%,酵母粉0.5%,葡萄糖0.5%,乙酸钠0.5%,柠檬酸二铵0.2%,吐温-80 0.1%,磷酸氢二钾0.2%,七水硫酸镁0.02%,一水硫酸锰0.005%,其余为水,pH调至6.0;
MRS固体培养基含如下质量百分数成分:酪蛋白胨1%,牛肉膏1%,酵母粉0.5%,葡萄糖0.5%,乙酸钠0.5%,柠檬酸二铵0.2%,吐温-80 0.1%,磷酸氢二钾0.2%,七水硫酸镁0.02%,一水硫酸锰0.005%,琼脂2%,其余为水,pH调至6.0;
最后,将筛选得到的优质鼠李糖乳杆菌突变株SG906进行传代培养以考察其遗传稳定性,每2天传代一次,传代10代,每隔一代进行摇瓶发酵测定菌株生物量、共轭亚油酸和γ-氨基丁酸的含量,结果表明鼠李糖乳杆菌突变株SG906传代过程中菌株生物量、共轭亚油酸和γ-氨基丁酸均无明显变化,具有良好的遗传稳定性;将获得遗传稳定的、能够同时高效积累共轭亚油酸和γ-氨基丁酸的鼠李糖乳杆菌SG906于2022年5月15日保藏于中国典型培养物保藏中心(简称CCTCC;地址:中国武汉,武汉大学;邮编:430072),保藏编号为CCTCC NO:M 2022615。
实施例2鼠李糖乳杆菌在发酵联产共轭亚油酸和γ-氨基丁酸中的应用
发酵联产共轭亚油酸和γ-氨基丁酸的方法,采用本发明提供的鼠李糖乳杆菌SG906,包括如下步骤:
A1、菌种活化:取50μL鼠李糖乳杆菌SG906甘油菌,接种至含MRS固体培养基的试管斜面,培养箱中于37℃培养48h进行菌种活化,再用5mL无菌生理盐水洗下菌体细胞,制备菌株细胞悬液,为活化后的菌株悬液;
A2、种子培养:取75mL经过步骤A1制得的活化后的菌株悬液按5%的接种量转接于含1.5L种子培养基的5L摇瓶,于37℃进行静置培养48h,制备种子液,进一步提高菌株的数量,强化菌株活力;
A3、鼠李糖乳杆菌SG906补料反馈发酵:采用20L全自动发酵罐(装液量为10L)进行鼠李糖乳杆菌SG906补料反馈发酵;取经过步骤A2培养好的1.5L种子培养液按15%的接种量无菌接种于10L发酵罐内液体培养基中,在发酵培养起始阶段,通气比为0.1(V/V·m),罐压为0.01Mpa,搅拌控制为100rpm,温度控制在37℃,初始葡萄糖的浓度控制在30g/L,通过流加70%的葡萄糖控制发酵体系中的残糖(以葡萄糖计)为0.5-1.0g/L;在发酵罐内OD600达到25后,通过流加亚油酸和谷氨酸控制发酵体系中的亚油酸浓度保持在0.01-0.1g/L和谷氨酸的浓度保持在1-5g/L;发酵罐培养全过程控制溶解氧在20-45%,pH为5.0-5.5发酵周期控制在72h,8000rpm离心10min,收集发酵上清液;
其中,发酵罐内液体培养基包括如下按质量百分比计的组份:葡萄糖0.5%,牛大骨蛋白胨2%,酵母粉2%,七水硫酸镁0.03%,一水硫酸锰0.01%,吐温-800.2%,谷氨酸5%,亚油酸0.2%,其余为水;
最终,测定发酵上清液中共轭亚油酸和γ-氨基丁酸含量,将经过步骤A3获得的发酵液上清进行共轭亚油酸和γ-氨基丁酸检测,参见图4,检测结果如下:鼠李糖乳杆菌SG906经72h补料反馈发酵,发酵液中共轭亚油酸的浓度最高可达7.95g/L,以亚油酸为底物转化率达到80.72%;发酵液中γ-氨基丁酸的浓度最高可达178.32g/L,转化率达98.56%,极具工业化运用价值。
实施例3鼠李糖乳杆菌SG906在制备复合功能发酵茶饮料中的应用
(1)制备茶叶浸提液:取1kg茶叶加入50kg蒸馏水,于100℃煮沸浸提15min,5000rpm离心20min取得茶叶浸提液液;
(2)鼠李糖乳杆菌SG906发酵茉莉花茶
取2.25L培养好的鼠李糖乳杆菌SG906种子液按5%的接种量接种至茉莉花茶浸提液发酵体系中,初始的鼠李糖乳杆菌SG906的菌落数控制在150CFU·mL-1,于37℃,100rpm进行发酵96h,得到复含共轭亚油酸和γ-氨基丁酸的益生菌发酵茶饮料,其CLA和GABA的含量分别为0.63g/L和2.14g/L。
茶叶浸提液发酵体系组成:葡萄糖5%,酵母提取物0.3%,大豆蛋白胨0.3%,奶粉1%,柠檬酸钠0.2%,谷氨酸5%,亚油酸0.08%,其余为茶叶浸提液,磷酸调节pH至5.0。
以上所述仅为本发明的实施例,并非因此限制本发明的专利范围,凡是利用本发明说明书内容所作的等效结构或等效流程变换,或直接或间接运用在其他相关的技术领域,均同理包括在本发明的专利保护范围内。
Claims (6)
1.一种联产共轭亚油酸和γ-氨基丁酸的鼠李糖乳杆菌,其特征在于:保藏编号为CCTCC M 2022615的鼠李糖乳杆菌SG906。
2.如权利要求1所述的鼠李糖乳杆菌在发酵联产共轭亚油酸和γ-氨基丁酸中的应用。
3.一种联产共轭亚油酸和γ-氨基丁酸的方法,其特征在于:采用如权利要求1所述的鼠李糖乳杆菌SG906依次经过活化培养、种子培养、发酵罐补料反馈培养高效联产共轭亚油酸和γ-氨基丁酸。
4.如权利要求4所述的一种联产共轭亚油酸和γ-氨基丁酸的方法,其特征在于:所述发酵罐内液体培养基pH为6.0~6.5,包括如下按质量百分比计的组份:葡萄糖0.5%,牛大骨蛋白胨2%,酵母粉2%,七水硫酸镁0.03%,一水硫酸锰0.01%,吐温-80 0.2%,谷氨酸5%,亚油酸0.2%,其余为水。
5.如权利要求4所述的一种联产共轭亚油酸和γ-氨基丁酸的方法,其特征在于:所述发酵罐培养周期划分为两个阶段:
(1)在发酵培养起始阶段,初始葡萄糖的浓度控制在30g/L,通过流加70%的葡萄糖控制发酵体系中的残糖(以葡萄糖计)为0.5-1.0g/L;
(2)在发酵罐内OD600达到25后,通过流加亚油酸和谷氨酸控制发酵体系中的亚油酸浓度保持在0.01-0.1g/L和谷氨酸的浓度保持在1-5g/L;
其中,所述发酵周期为72h,发酵罐培养全过程控制溶解氧在20-45%。
6.如权利要求1所述的鼠李糖乳杆菌在制备复合功能发酵茶饮料中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210790287.7A CN114958694B (zh) | 2022-07-06 | 2022-07-06 | 一种联产共轭亚油酸和γ-氨基丁酸的鼠李糖乳杆菌及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210790287.7A CN114958694B (zh) | 2022-07-06 | 2022-07-06 | 一种联产共轭亚油酸和γ-氨基丁酸的鼠李糖乳杆菌及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114958694A true CN114958694A (zh) | 2022-08-30 |
CN114958694B CN114958694B (zh) | 2023-05-02 |
Family
ID=82967703
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210790287.7A Active CN114958694B (zh) | 2022-07-06 | 2022-07-06 | 一种联产共轭亚油酸和γ-氨基丁酸的鼠李糖乳杆菌及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114958694B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115895974A (zh) * | 2022-12-23 | 2023-04-04 | 闽榕茶业有限公司 | 一株富硒且高产γ-氨基丁酸的植物乳杆菌及其应用 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101068918A (zh) * | 2004-08-16 | 2007-11-07 | Pl生物株式会社 | 具有减少身体脂肪活性的鼠李糖乳杆菌以及包含它们的食品 |
CN101228262A (zh) * | 2005-07-21 | 2008-07-23 | 株式会社益力多本社 | 新型双歧杆菌属细菌及其利用 |
CN102144667A (zh) * | 2011-02-15 | 2011-08-10 | 内蒙古伊利实业集团股份有限公司 | 生物转化法制备富含共轭亚油酸的活性乳酸菌饮料的方法 |
CN104839680A (zh) * | 2015-04-13 | 2015-08-19 | 劲膳美生物科技股份有限公司 | 心血管疾病医学配方食品 |
CN110143360A (zh) * | 2018-02-12 | 2019-08-20 | 福建奥正投资发展有限公司 | 具有环筒状的腔筒结构的容器封闭装置,包装容器及其应用 |
CN111955720A (zh) * | 2020-07-11 | 2020-11-20 | 杭州劲膳美健康管理有限公司 | 一种产妇产后催乳特殊膳食及其制备方法 |
US20210254056A1 (en) * | 2017-05-05 | 2021-08-19 | Camp4 Therapeutics Corporation | Identification and targeted modulation of gene signaling networks |
WO2021206480A1 (en) * | 2020-04-08 | 2021-10-14 | Psomagen, Inc. | Composition and method for an antibiotic-inducing imbalance in microbiota |
CN115074290A (zh) * | 2022-07-06 | 2022-09-20 | 福建生物工程职业技术学院 | 一种联产苯乳酸和γ-氨基丁酸的干酪乳杆菌及其应用 |
-
2022
- 2022-07-06 CN CN202210790287.7A patent/CN114958694B/zh active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101068918A (zh) * | 2004-08-16 | 2007-11-07 | Pl生物株式会社 | 具有减少身体脂肪活性的鼠李糖乳杆菌以及包含它们的食品 |
CN101228262A (zh) * | 2005-07-21 | 2008-07-23 | 株式会社益力多本社 | 新型双歧杆菌属细菌及其利用 |
CN102144667A (zh) * | 2011-02-15 | 2011-08-10 | 内蒙古伊利实业集团股份有限公司 | 生物转化法制备富含共轭亚油酸的活性乳酸菌饮料的方法 |
CN104839680A (zh) * | 2015-04-13 | 2015-08-19 | 劲膳美生物科技股份有限公司 | 心血管疾病医学配方食品 |
US20210254056A1 (en) * | 2017-05-05 | 2021-08-19 | Camp4 Therapeutics Corporation | Identification and targeted modulation of gene signaling networks |
CN110143360A (zh) * | 2018-02-12 | 2019-08-20 | 福建奥正投资发展有限公司 | 具有环筒状的腔筒结构的容器封闭装置,包装容器及其应用 |
WO2021206480A1 (en) * | 2020-04-08 | 2021-10-14 | Psomagen, Inc. | Composition and method for an antibiotic-inducing imbalance in microbiota |
CN111955720A (zh) * | 2020-07-11 | 2020-11-20 | 杭州劲膳美健康管理有限公司 | 一种产妇产后催乳特殊膳食及其制备方法 |
CN115074290A (zh) * | 2022-07-06 | 2022-09-20 | 福建生物工程职业技术学院 | 一种联产苯乳酸和γ-氨基丁酸的干酪乳杆菌及其应用 |
Non-Patent Citations (2)
Title |
---|
DUYGU AĞAGÜNDÜZ等: "Lactic acid bacteria as pro-technological, bioprotective and health-promoting cultures in the dairy food industry" * |
方丽等: "响应面法优化鼠李糖乳杆菌产共轭亚油酸的转化条件" * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115895974A (zh) * | 2022-12-23 | 2023-04-04 | 闽榕茶业有限公司 | 一株富硒且高产γ-氨基丁酸的植物乳杆菌及其应用 |
CN115895974B (zh) * | 2022-12-23 | 2024-02-13 | 闽榕茶业有限公司 | 一株富硒且高产γ-氨基丁酸的植物乳杆菌及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN114958694B (zh) | 2023-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102191202B (zh) | 一种乳酸菌的高密度培养方法 | |
CN1243101C (zh) | 一种食品功能因子γ-氨基丁酸的制备方法 | |
CN109182171B (zh) | 高产γ-氨基丁酸的诱变菌株及其生物制剂 | |
CN109593683B (zh) | 副干酪乳杆菌及其应用 | |
CN101074426B (zh) | 一种植物乳杆菌发酵制备富含共轭亚油酸豆粕饲料的方法 | |
RU2009116440A (ru) | Способ культивирования, благоприятствующий продуцированию к-витамина молочнокислыми бактериями, и его применение в производстве пищевых продуктов | |
CN101874546A (zh) | 微生物发酵饲料及其制备方法 | |
CN108034599B (zh) | 一株源自白酒酿造体系的高效合成γ-氨基丁酸的短乳杆菌 | |
CN103173371A (zh) | 酿酒酵母与嗜酸乳杆菌的饲料用复合微生物制剂的生产 | |
CN110157650B (zh) | 一株分离自母乳的乳双歧杆菌m8及其应用 | |
CN115074290B (zh) | 一种联产苯乳酸和γ-氨基丁酸的干酪乳杆菌及其应用 | |
CN115261264A (zh) | 一株副干酪乳酪杆菌pc804及其应用 | |
CN110122567A (zh) | 具有抗氧化功能的复合发酵乳及其制备方法 | |
CN109294940A (zh) | 玉米乳杆菌诱变菌及高产乳酸的用途 | |
CN114958694B (zh) | 一种联产共轭亚油酸和γ-氨基丁酸的鼠李糖乳杆菌及应用 | |
CN114304379A (zh) | 一种含有复合微生物菌剂的发酵饲料的制备方法 | |
CN115895974B (zh) | 一株富硒且高产γ-氨基丁酸的植物乳杆菌及其应用 | |
CN109628350B (zh) | 植物乳杆菌及其应用 | |
CN112391317B (zh) | 一种生产燕窝酸的益生菌株组合物及用途 | |
CN109971675A (zh) | 一株植物乳杆菌scuec6菌株及其应用 | |
CN112592854B (zh) | 高密度保加利亚乳杆菌的发酵培养基及发酵方法和应用 | |
CN109423467A (zh) | 一种乳酸高产的植物乳杆菌及其在食品和饲料领域的用途 | |
KR101685768B1 (ko) | 발효렌틸콩의 제조방법 | |
CN113930367A (zh) | 一株具有降胆固醇性能的乳酸菌及其应用 | |
CN113528599A (zh) | 一种高效螯合型酵素肽的生产方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |